Coordinated by Montpellier University Medical Center, France, the international study IN EXTREMIS-LASTE, representing a groundbreaking contribution to stroke research was published today in the New England Journal of Medicine.MONTPELLIER, France, May 9, 2024 /PRNewswire/ -- 'LASTE' (LArge Stroke Therapy Evaluation), a prospective, randomized, controlled trial co-led by Professor Vincent Costalat (neuroradiologist, Montpellier, France) and Dr.

在法国蒙彼利埃大学医学中心的协调下，这项关于EXTREMIS-LASTE的国际研究今天在《新英格兰医学杂志》上发表，该研究代表了对中风研究的开创性贡献。法国蒙彼利埃，2024年5月9日/PRNewswire/--“LASTE”（大型卒中治疗评估），这是一项前瞻性，随机，对照试验，由Vincent Costalat教授（法国蒙彼利埃神经放射学家）和Dr。

Caroline Arquizan (vascular neurologist, Montpellier, France), in addition to Dr. Bertrand Lapergue (vascular neurologist, Hospital Foch, Paris, France) and Prof. Tudor Jovin (interventional and vascular neurologist, Cooper University Hospital, Camden, NJ, USA)  has the potential to disrupt current systems of care involving triage and management of patients with acute stroke due to large vessel occlusion by demonstrating that even those patients with the largest areas of 'irreversibly' damaged brain as assessed by state-of-the-art imaging technologies still benefit from mechanical reperfusion.

Caroline Arquizan（法国蒙彼利埃的血管神经病学家）以及Bertrand Lapergue博士（法国巴黎Foch医院的血管神经病学家）和Tudor Jovin教授（美国新泽西州卡姆登库珀大学医院的介入和血管神经病学家）有可能破坏目前的护理系统，包括对大血管闭塞引起的急性卒中患者进行分流和管理，证明即使是那些大脑面积最大的患者，通过最先进的成像技术评估，仍然受益于机械再灌注。

.

.

Continue Reading

继续阅读

From letf to right, Caroline Arquizan, MD, Chief of Neurovascular Department of University Hospital of Montpellier, France, Vincent Costalat, MD, PhD, Professor of Radiology and Chief of Neuroradiology Department of University Hospital of Montpellier, France Prof. Tudor Jovin, Chair of the Neurology Department of Cooper University Medical Center in Camden, New Jersey, USA Bertrand Lapergue, MD, PhD, Chief of Neurology and Neurovascular Department from Hospital Foch in Paris, France.

从左到右，法国蒙彼利埃大学医院神经血管科主任卡罗琳·阿奎赞（Caroline Arquizan）医学博士，法国蒙彼利埃大学医院放射学教授兼神经放射科主任文森特·科斯塔尔特（Vincent Costalat）医学博士，法国蒙彼利埃大学医院放射学教授兼神经放射科主任图多尔·乔文（Tudor Jovin）教授，美国新泽西州卡姆登库珀大学医学中心神经病学系主任贝特朗·拉佩格（Bertrand Lapergue）医学博士，法国巴黎福克斯医院神经病学和神经血管科主任。

Illustration of LASTE clinical trial learnings – Brain parts that brain imaging suggests is dead may not entirely be so. Vincent Costalat, MD, PhD, Professor of Radiology and Chief of Neuroradiology Department of University Hospital of Montpellier, France Les enseignements de l’étude LASTE – Les parties du cerveau que l’on croyait détruites d’après les imageries cérébrales ne le sont pas entièrement.

最后一次临床试验学习的说明——脑成像表明死亡的脑部分可能并不完全死亡。Vincent Costalat，医学博士，放射学教授，法国蒙彼利埃大学医院神经放射学系主任

Vincent Costalat, MD, PhD, Professor of Radiology and Chief of Neuroradiology Department of University Hospital of Montpellier, France.

Vincent Costalat，医学博士，博士，放射学教授，法国蒙彼利埃大学医院神经放射学系主任。

Trial of Thrombectomy for Stroke with a Large Infract of Unrestrited Size, published in the New England Journal of Medicine https://www.nejm.org/

血栓切除术治疗无限制大面积梗死的中风试验，发表在《新英格兰医学杂志》上https://www.nejm.org/

Since mechanical thrombectomy, a technique that aims to restore blood flow in stroke patients who experience sudden occlusion of a brain artery, by removing the blockage with device-based technologies, became standard of care in 2015, physicians selected for such intervention only stroke patients who displayed limited amounts of brain damage on brain imaging.

自从机械血栓切除术（一种旨在通过使用基于设备的技术消除阻塞来恢复脑动脉突然闭塞的中风患者血流的技术）于2015年成为标准治疗以来，医生仅选择在脑成像中显示有限脑损伤的中风患者进行此类干预。

This was based on the principle that restoration of blood flow to large areas of irreversibly damaged brain  is not only futile but can also cause additional damage due to an increased risk of bleeding in the brain among other detrimental effects of reperfusion.  .

这是基于这样的原则，即恢复大面积不可逆损伤大脑的血流不仅是徒劳的，而且还可能由于大脑出血风险增加以及再灌注的其他有害影响而导致额外的损伤。。

Yet, an international network of stroke centers led by the Montpellier University Hospital investigators has proven the opposite. The multicenter therapeutic trial 'LASTE' was conducted in France (26 centers) and Spain (7 centers) for 3 years. The trial aimed to select patients hitherto considered 'irrecoverable' in common practice due to unrestrictedly large areas of irreversibly compromised brain presenting with acute stroke due to large vessel occlusion within 7 hours of stroke onset to test the hypothesis that reperfusion of brain tissue considered dead could improve their outcome not only in term of survival but also in terms of functional recovery.IN EXTREMIS TRIALS LASTE and MOSTE are sponsored by an Industrial unrestricted grant co-founded by 5 industrial partners (BALT, CERENOVUS, MEDTRONIC, MICROVENTION, STRYKER).Photo: https://mma.prnewswire.com/media/2407575/CHU_de_Montpellier_1.jpgPhoto: https://mma.prnewswire.com/media/2407574/CHU_de_Montpellier_2.jpgLogo: https://mma.prnewswire.com/media/2407576/CHU_de_Montpellier_Logo.jpgContacts :v-costalat@chu-montpellier.frc-arquizan@chu-montpellier.frSOURCE CHU de Montpellier.

然而，蒙彼利埃大学医院调查人员领导的国际中风中心网络却证明了相反的情况。多中心治疗试验“LASTE”在法国（26个中心）和西班牙（7个中心）进行了3年。该试验旨在选择迄今为止在常规实践中被认为是“不可恢复”的患者，因为在中风发作后7小时内，由于大血管闭塞，大脑不可逆地受到不受限制的大面积损害，出现急性中风，以检验脑组织再灌注被认为死亡的假设不仅可以改善生存率，还可以改善功能恢复。在极限试验中，LASTE和MOSTE由5个工业合作伙伴（BALT，CERENOVUS，MEDTRONIC，MICROVENTION，STRYKER）共同创立的工业无限制拨款资助。照片：https://mma.prnewswire.com/media/2407575/CHU_de_Montpellier_1.jpgPhoto:（笑声）https://mma.prnewswire.com/media/2407574/CHU_de_Montpellier_2.jpgLogo:（笑声）https://mma.prnewswire.com/media/2407576/CHU_de_Montpellier_Logo.jpgContacts时间：v-costalat@chu-montpellier.frc-arquizan@chu-montpellier.frSOURCE chu de montpellier。